(Kevin Frayer/Getty Images)

Steve Madden steps up as Citi upgrades stock on a Y2K fashion rebound

Citi analysts say the chunky shoe icon may have bottomed out as social buzz builds and tariff pressures ease.

7/17/25 1:17PM

Steve Madden shares gained nearly 6% Thursday after Citi upgraded the struggling footwear brand to “buy” from “neutral” and raised its price target to $32 — more than 20% above current trading levels.

The brand has lost over a third of its value this year, but Citi analysts think the worst may now be behind the brand as fashion trends shift in its favor and social media buzz helps drive demand for its designer dupe shoe styles. Citi also highlighted the company’s pivot away from China-based manufacturing, which could help curb exposure to tariff shocks.

Citi now expects earnings per share of $2.15 in 2026, well ahead of Wall Street’s $1.84 estimate. The bank’s analysts expect revenue to climb 12% next year, boosted by rising demand for the company’s dress shoes and contributions from its February acquisition of UK-based luxury brand Kurt Geiger. Analysts added that any Q3 guidance when the company reports on July 30 could also help lift spirits.

Steve Madden shares are still down about 41.5% over the past year.

Luke Kawa

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

Nia Warfield, Luke Kawa

S&P 500 falls as rate-cut optimism fizzles

The S&P 500 gave up early gains to close down 0.3%, while the Nasdaq 100 eked out a 0.1% advance and the Russell 2000 outperformed, rising 0.5%.

Nia Warfield

11h

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

RFK Jr., HHS to Link Autism to Tylenol Use in Pregnancy and Folate Deficiencies

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

Max Knoblauch

11h

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Matt Phillips

13h

Palantir slips under 50-day moving average, amid momo reversal

What goes up, doesn’t always keep going up.

Palantir CEO Alex Karp PLTR insane valuation

Steve Madden steps up as Citi upgrades stock on a Y2K fashion rebound

More Markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

RFK Jr., HHS to Link Autism to Tylenol Use in Pregnancy and Folate Deficiencies

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

Latest Stories